

Low-grade glioma immunotherapy

- 1: Zhang N, Zhang H, Wu W, Zhou R, Li S, Wang Z, Dai Z, Zhang L, Liu F, Liu Z, Zhang J, Luo P, Liu Z, Cheng Q. Machine learning-based identification of tumor- infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. *Theranostics*. 2022 Aug 8;12(13):5931-5948. doi: 10.7150/thno.74281. PMID: 35966587; PMCID: PMC9373811.
- 2: Qiao Q, Wang Y, Zhang R, Pang Q. Autophagy related DNA methylation signature predict clinical prognosis and immune microenvironment in low-grade glioma. *Transl Cancer Res*. 2022 Jul;11(7):2157-2174. doi: 10.21037/tcr-22-310. PMID: 35966301; PMCID: PMC9372237.
- 3: Wang W, Zhang J, Wang Y, Xu Y, Zhang S. Identifies microtubule-binding protein *CSPP1* as a novel cancer biomarker associated with [Ferroptosis](#) and tumor microenvironment. *Comput Struct Biotechnol J*. 2022 Jun 24;20:3322-3335. doi: 10.1016/j.csbj.2022.06.046. PMID: 35832625; PMCID: PMC9253833.
- 4: Tan S, Spear R, Zhao J, Sun X, Wang P. Comprehensive Characterization of a Novel E3-Related Gene Signature With Implications in Prognosis and Immunotherapy of Low-Grade Gliomas. *Front Genet*. 2022 Jun 27;13:905047. doi: 10.3389/fgene.2022.905047. PMID: 35832194; PMCID: PMC9271851.
- 5: Bishop E, Dimitrova M, Froggatt A, Estevez-Cebrero M, Storer LCD, Mussai F, Paine S, Grundy RG, Dandapani M. Characterisation of Expression the Arginine Pathway Enzymes in Childhood Brain Tumours to Determine Susceptibility to Therapeutic Arginine Depletion. *Biomed Res Int*. 2022 Jun 22;2022:9008685. doi: 10.1155/2022/9008685. PMID: 35782058; PMCID: PMC9242779.
- 6: Greer HR, Miller K, Samay S, Nellan A, Green AL. Investigation of white blood cell characteristics in cerebrospinal fluid samples at pediatric brain tumor diagnosis. *J Neurooncol*. 2022 Jun 22. doi: 10.1007/s11060-022-04065-w. Epub ahead of print. PMID: 35731362.
- 7: Zhang S, Xiao X, Wang Y, Song T, Li C, Bao H, Liu Q, Sun G, Sun X, Su T, Fu T, Wang Y, Liang P. Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma. *Front Genet*. 2022 Jun 2;13:899125. doi: 10.3389/fgene.2022.899125. PMID: 35719378; PMCID: PMC9204856.
- 8: Xia H, Deng L, Meng S, Liu X, Zheng C. Single-Cell Transcriptome Profiling Signatures and Alterations of Microglia Associated With Glioblastoma Associate Microglia Contribution to Tumor Formation. *Pathol Oncol Res*. 2022 May 25;28:1610067. doi: 10.3389/pore.2022.1610067. PMID: 35693633; PMCID: PMC9176381.
- 9: Shao D, Li Y, Wu J, Zhang B, Xie S, Zheng X, Jiang Z. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma. *Front Genet*. 2022 May 26;13:903117. doi: 10.3389/fgene.2022.903117. PMID: 35692827; PMCID: PMC9178125.
- 10: Teng C, Zhu Y, Li Y, Dai L, Pan Z, Wanggou S, Li X. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. *Front Immunol*. 2022 May 23;13:899710. doi: 10.3389/fimmu.2022.899710. PMID: 35677036; PMCID: PMC9168984.
- 11: Mohammed SM, Elesawy YF, Abd El Aziz AM, Khairy RA. The Pathological Evaluation of Autophagy-Related Protein (LC3B) and Its Association with the Infiltration of Immune Cells in Glioma. *Asian Pac J*

Cancer Prev. 2022 May 1;23(5):1777-1784. doi: 10.31557/APJCP.2022.23.5.1777. PMID: 35633564.

12: Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. *J Immunother Cancer*. 2022 May;10(5):e004644. doi: 10.1136/jitc-2022-004644. PMID: 35606087; PMCID: PMC9174833.

13: Li B, Wang F, Wang N, Hou K, Du J. Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures. *Front Immunol*. 2022 Apr 27;13:871564. doi: 10.3389/fimmu.2022.871564. PMID: 35572524; PMCID: PMC9094412.

14: Feng Y, Wang Y, Guo K, Feng J, Shao C, Pan M, Ding P, Liu H, Duan H, Lu D, Wang Z, Zhang Y, Zhang Y, Han J, Li X, Yan X. The value of *WNT5A* as prognostic and immunological biomarker in pan-cancer. *Ann Transl Med*. 2022 Apr;10(8):466. doi: 10.21037/atm-22-1317. PMID: 35571400; PMCID: PMC9096401.

15: Yan X, Ji H, Liu Z, Ma S, Dong J, Jiang X, Hu X, Wang F, Zhao H, Jin J, Zhang J, Wang N, Du J, Hu S. Characterization of the *Ferroptosis*-Related Genes for Prognosis and Immune Infiltration in Low-Grade Glioma. *Front Genet*. 2022 Apr 26;13:880864. doi: 10.3389/fgene.2022.880864. PMID: 35559020; PMCID: PMC9086515.

16: Sun L, Li B, Wang B, Li J, Li J. Construction of a Risk Model to Predict the Prognosis and Immunotherapy of Low-Grade Glioma Ground on 7 *Ferroptosis*-Related Genes. *Int J Gen Med*. 2022 May 5;15:4697-4716. doi: 10.2147/IJGM.S352773. PMID: 35548585; PMCID: PMC9085428.

17: Li J, Huang Q, Mo L. Comprehensive Analysis of Phagocytosis-Related Regulators to Aid Prognostic Prediction and Immunotherapy in Patients with Low- Grade Glioma. *Dis Markers*. 2022 Apr 12;2022:4142684. doi: 10.1155/2022/4142684. PMID: 35510040; PMCID: PMC9061072.

18: Jia Y, Cheng X, Liang W, Lin S, Li P, Yan Z, Zhang M, Ma W, Hu C, Wang B, Liu Z. CLSPN is a potential biomarker associated with poor prognosis in low- grade gliomas based on a multi-database analysis. *Curr Res Transl Med*. 2022 Apr 26;70(4):103345. doi: 10.1016/j.retram.2022.103345. Epub ahead of print. PMID: 35487167.

19: Silva M, Vivancos C, Duffau H. The Concept of «Peritumoral Zone» in Diffuse Low-Grade Gliomas: Oncological and Functional Implications for a Connectome- Guided Therapeutic Attitude. *Brain Sci*. 2022 Apr 15;12(4):504. doi: 10.3390/brainsci12040504. PMID: 35448035; PMCID: PMC9032126.

20: Haddock S, Alban TJ, Turcan Ş, Husic H, Rosiek E, Ma X, Wang Y, Bale T, Desrichard A, Makarov V, Monette S, Wu W, Gardner R, Manova K, Boire A, Chan TA. Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. *Neoplasia*. 2022 Jun;28:100790. doi: 10.1016/j.neo.2022.100790. Epub 2022 Apr 7. PMID: 35398668; PMCID: PMC9014446.

21: Agarwal P, Beale OM, Zhang X, Sandlesh P, Jaman E, Amankulor N. Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma Using RNA Sequencing Expression Data. *World Neurosurg*. 2022 Jul;163:e349-e362. doi: 10.1016/j.wneu.2022.03.123. Epub 2022 Apr 4. PMID: 35390499.

22: Zhang P, Liu G, Hu J, Chen S, Wang B, Peng P, Yu X, Guo D. Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low- Grade Gliomas. *Front Immunol*. 2022

Mar 16;13:824586. doi: 10.3389/fimmu.2022.824586. PMID: 35371015; PMCID: PMC8966496.

23: Zhang J, Liu M, Fang Y, Li J, Chen Y, Jiao S. TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients. *Front Genet.* 2022 Mar 11;13:720651. doi: 10.3389/fgene.2022.720651. PMID: 35368662; PMCID: PMC8974296.

24: Zhou Z, Wei J, Jiang W. Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. *Sci Rep.* 2022 Mar 31;12(1):5457. doi: 10.1038/s41598-022-09549-3. PMID: 35361903; PMCID: PMC8971489.

25: Rafique Z, Awan MW, Iqbal S, Usmani NN, Kamal MM, Arshad W, Ahmad M, Mumtaz H, Ahmad S, Hasan M. Diagnostic Accuracy of Magnetic Resonance Spectroscopy in Predicting the Grade of Glioma Keeping Histopathology as the Gold Standard. *Cureus.* 2022 Feb 9;14(2):e22056. doi: 10.7759/cureus.22056. PMID: 35340513; PMCID: PMC8916061.

26: Yang Y, Tian Y, Li Q, Jiang R, Zhang J. Uncovering the Immune Cell Infiltration Landscape in Low-Grade Glioma for Aiding Immunotherapy. *J Oncol.* 2022 Mar 11;2022:3370727. doi: 10.1155/2022/3370727. PMID: 35310911; PMCID: PMC8933094.

27: Bai Z, Wang X, Zhang Z. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma. *Front Genet.* 2022 Feb 25;13:655169. doi: 10.3389/fgene.2022.655169. PMID: 35281815; PMCID: PMC8914514.

28: Li S, Gao P, Dai X, Ye L, Wang Z, Cheng H. New prognostic biomarker *CMTM3* in low-grade glioma and its immune infiltration. *Ann Transl Med.* 2022 Feb;10(4):206. doi: 10.21037/atm-22-526. PMID: 35280380; PMCID: PMC8908177.

29: Wang J, Ren J, Liu J, Zhang L, Yuan Q, Dong B. Identification and Verification of the **Ferroptosis**- and Pyroptosis-Associated Prognostic Signature for low-grade Glioma. *Bosn J Basic Med Sci.* 2022 Mar 9. doi: 10.17305/bjbms.2021.6888. Epub ahead of print. PMID: 35276059.

30: Henderson JJ, Das A, Morgenstern DA, Sudhaman S, Bianchi V, Chung J, Negm L, Edwards M, Kram DE, Osborn M, Hawkins C, Bouffet E, Cho YJ, Tabori U. Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study. *JCO Precis Oncol.* 2022 Mar;6:e2100286. doi: 10.1200/PO.21.00286. PMID: 35235414; PMCID: PMC8906457.

31: Zhang J, Wang Z, Zhang H, Dai Z, Liang X, Li S, Zhang X, Liu F, Liu Z, Yang K, Cheng Q. Functions of RNF Family in the Tumor Microenvironment and Drugs Prediction in Grade II/III Gliomas. *Front Cell Dev Biol.* 2022 Feb 9;9:754873. doi: 10.3389/fcell.2021.754873. PMID: 35223862; PMCID: PMC8864229.

32: Sim HW, Galanis E, Khasraw M. PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. *Cancers (Basel).* 2022 Feb 16;14(4):1003. doi: 10.3390/cancers14041003. PMID: 35205750; PMCID: PMC8869934.

33: Zhou Z, Wei J, Lu B, Jiang W, Bao Y, Li L, Wang W. Comprehensive Characterization of Pyroptosis Patterns with Implications in Prognosis and Immunotherapy in Low-Grade Gliomas. *Front Genet.* 2022 Feb 7;12:763807. doi: 10.3389/fgene.2021.763807. PMID: 35198000; PMCID: PMC8859270.

34: Liu H, Weng J. A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma. *Gene.* 2022 May 15;822:146325. doi: 10.1016/j.gene.2022.146325. Epub 2022 Feb 17. PMID: 35183683.

- 35: Ji Q, Huang K, Jiang Y, Lei K, Tu Z, Luo H, Zhu X. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower- grade gliomas. *Cancer Med*. 2022 May;11(9):2020-2035. doi: 10.1002/cam4.4603. Epub 2022 Feb 10. PMID: 35142109; PMCID: PMC9089222.
- 36: Zhang X, Kim WJ, Rao AV, Jaman E, Deibert CP, Sandlesh P, Krueger K, Allen JC, Amankulor NM. In vivo efficacy of decitabine as a natural killer cell- mediated immunotherapy against isocitrate dehydrogenase mutant gliomas. *Neurosurg Focus*. 2022 Feb;52(2):E3. doi: 10.3171/2021.11.FOCUS21489. PMID: 35104792.
- 37: Haddad AF, Young JS, Oh JY, Okada H, Aghi MK. The immunology of low-grade gliomas. *Neurosurg Focus*. 2022 Feb;52(2):E2. doi: 10.3171/2021.11.FOCUS21587. PMID: 35104791; PMCID: PMC9283531.
- 38: Mao C, Zhuang SM, Xia Z, Xiao ZW, Huang CX, Su Q, Chen J, Liao J. Pan-cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma. *J Leukoc Biol*. 2022 Jan 24. doi: 10.1002/JLB.5MA1221-468R. Epub ahead of print. PMID: 35075694.
- 39: Wang Y, Xu Y, Zhang Y. A new signature based on alternative polyadenylation for prognostic prediction and therapeutic responses in low-grade glioma. *Aging (Albany NY)*. 2022 Jan 18;14(2):826-844. doi: 10.18632/aging.203844. Epub 2022 Jan 18. PMID: 35042833; PMCID: PMC8833112.
- 40: Larkin T, Das A, Bianchi V, Sudhaman S, Chung J, Alsafwani N, Negm L, Yachnis A, Blatt J, Hawkins C, Bouffet E, Tabori U, Gururangan S. Upfront Adjuvant Immunotherapy of Replication Repair-Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach. *JCO Precis Oncol*. 2021 Nov;5:1426-1431. doi: 10.1200/PO.21.00153. PMID: 34994637.
- 41: Otazu GK, Dayyani M, Badie B. Role of RAGE and Its Ligands on Inflammatory Responses to Brain Tumors. *Front Cell Neurosci*. 2021 Dec 16;15:770472. doi: 10.3389/fncel.2021.770472. PMID: 34975408; PMCID: PMC8716782.
- 42: Liu W, Li C, Wu Y, Xu W, Chen S, Zhang H, Huang H, Zhao S, Wang J. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas. *Front Cell Dev Biol*. 2021 Nov 25;9:725764. doi: 10.3389/fcell.2021.725764. PMID: 34900988; PMCID: PMC8661096.
- 43: Li G, Wu Z, Gu J, Zhu Y, Zhang T, Wang F, Huang K, Gu C, Xu K, Zhan R, Shen J. Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy. *Front Cell Dev Biol*. 2021 Nov 23;9:755776. doi: 10.3389/fcell.2021.755776. PMID: 34888308; PMCID: PMC8650219.
- 44: Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. *J Clin Invest*. 2022 Feb 1;132(3):e151239. doi: 10.1172/JCI151239. PMID: 34882581; PMCID: PMC8803342.
- 45: Lu L, Hu Y, Wang C, Jiang F, Wu C. Methylation and Expression of the Exercise-Related TLR1 Gene Is Associated With low-grade glioma Prognosis and Outcome. *Front Mol Biosci*. 2021 Nov 16;8:747933. doi: 10.3389/fmolb.2021.747933. PMID: 34869584; PMCID: PMC8635206.

46: Melcher V, Kerl K. The Growing Relevance of Immunoregulation in Pediatric Brain Tumors. *Cancers (Basel)*. 2021 Nov 9;13(22):5601. doi: 10.3390/cancers13225601. PMID: 34830753; PMCID: PMC8615622.

47: Wang M, Jia J, Cui Y, Peng Y, Jiang Y. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low- Grade Gliomas. *Brain Sci*. 2021 Nov 18;11(11):1529. doi: 10.3390/brainsci11111529. PMID: 34827528; PMCID: PMC8615402.

48: Wang M, Jia J, Cui Y, Peng Y, Jiang Y. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. *Cell Death Dis*. 2021 Nov 9;12(11):1065. doi: 10.1038/s41419-021-04359-3. PMID: 34753903; PMCID: PMC8578373.

49: Zhu H, Hu X, Gu L, Jian Z, Li L, Hu S, Qiu S, Xiong X. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment. *Front Genet*. 2021 Oct 14;12:759953. doi: 10.3389/fgene.2021.759953. PMID: 34721547; PMCID: PMC8553001.

50: Luo C, Wang S, Liao W, Zhang S, Xu N, Xie W, Zhang Y. Upregulation of the APOBEC3 Family Is Associated with a Poor Prognosis and Influences Treatment Response to Raf Inhibitors in low-grade glioma . *Int J Mol Sci*. 2021 Sep 27;22(19):10390. doi: 10.3390/ijms221910390. PMID: 34638749; PMCID: PMC8508917.

51: Lin WW, Ou GY, Zhao WJ. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. *J Cell Mol Med*. 2021 Nov;25(21):10111-10125. doi: 10.1111/jcmm.16947. Epub 2021 Oct 1. PMID: 34597473; PMCID: PMC8572778.

52: Lu X, Li C, Xu W, Wu Y, Wang J, Chen S, Zhang H, Huang H, Huang H, Liu W. Malignant Tumor Purity Reveals the Driven and Prognostic Role of *CD3E* in Low-Grade Glioma Microenvironment. *Front Oncol*. 2021 Sep 7;11:676124. doi: 10.3389/fonc.2021.676124. PMID: 34557404; PMCID: PMC8454269.

53: Liu YS, Huang BR, Lin CJ, Shen CK, Lai SW, Chen CW, Lin HJ, Lin CH, Hsieh YC, Lu DY. Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression. *Cancers (Basel)*. 2021 Aug 28;13(17):4357. doi: 10.3390/cancers13174357. PMID: 34503167; PMCID: PMC8430966.

54: Zhang H, Luo YB, Wu W, Zhang L, Wang Z, Dai Z, Feng S, Cao H, Cheng Q, Liu Z. The molecular feature of macrophages in tumor immune microenvironment of glioma patients. *Comput Struct Biotechnol J*. 2021 Aug 14;19:4603-4618. doi: 10.1016/j.csbj.2021.08.019. PMID: 34471502; PMCID: PMC8383063.

55: Peng S, Wang G, Cheng Z, Guo Z. IRF7 as an Immune-Related Prognostic Biomarker and Associated with Tumor Microenvironment in Low-Grade Glioma. *Int J Gen Med*. 2021 Aug 12;14:4381-4393. doi: 10.2147/IJGM.S324307. PMID: 34413671; PMCID: PMC8371259.

56: Xiang Z, Chen X, Lv Q, Peng X. A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients. *Front Genet*. 2021 Aug 2;12:697819. doi: 10.3389/fgene.2021.697819. PMID: 34408772; PMCID: PMC8365518.

57: Cheng Q, Duan W, He S, Li C, Cao H, Liu K, Ye W, Yuan B, Xia Z. Multi-Omics Data Integration Analysis of an Immune-Related Gene Signature in LGG Patients With Epilepsy. *Front Cell Dev Biol*. 2021 Jul 16;9:686909. doi: 10.3389/fcell.2021.686909. PMID: 34336837; PMCID: PMC8322853.

- 58: Plant-Fox AS, O'Halloran K, Goldman S. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. *Curr Probl Cancer*. 2021 Aug;45(4):100777. doi: 10.1016/j.currproblcancer.2021.100777. Epub 2021 Jul 16. PMID: 34303558.
- 59: Merickel JL, Pluhar GE, Rendahl A, O'Sullivan MG. Prognostic histopathologic features of canine glial tumors. *Vet Pathol*. 2021 Sep;58(5):945-951. doi: 10.1177/03009858211025795. Epub 2021 Jul 5. PMID: 34219560.
- 60: Rosso DA, Rosato M, Iturrizaga J, González N, Shiromizu CM, Keitelman IA, Coronel JV, Gómez FD, Amaral MM, Rabadan AT, Salamone GV, Jancic CC. Glioblastoma cells potentiate the induction of the Th1-like profile in phosphoantigen-stimulated $\gamma\delta$ T lymphocytes. *J Neurooncol*. 2021 Jul;153(3):403-415. doi: 10.1007/s11060-021-03787-7. Epub 2021 Jun 14. PMID: 34125375.
- 61: Singh G, Manjila S, Sakla N, True A, Wardeh AH, Beig N, Vaysberg A, Matthews J, Prasanna P, Spektor V. Radiomics and radiogenomics in gliomas: a contemporary update. *Br J Cancer*. 2021 Aug;125(5):641-657. doi: 10.1038/s41416-021-01387-w. Epub 2021 May 6. PMID: 33958734; PMCID: PMC8405677.
- 62: Zhang Y, Yang X, Zhu XL, Wang ZZ, Bai H, Zhang JJ, Hao CY, Duan HB. A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma. *Front Oncol*. 2021 Apr 16;11:643159. doi: 10.3389/fonc.2021.643159. PMID: 33937046; PMCID: PMC8085360.
- 63: Cernadas J, Vasconcelos MJ, Fernandes AP, Carneiro-Leão L, Gil-da-Costa MJ. Desensitization to carboplatin in low-grade glioma. A revision of 100 treatments in children. *Pediatr Allergy Immunol*. 2021 Aug;32(6):1388-1391. doi: 10.1111/pai.13525. Epub 2021 May 7. PMID: 33893665.
- 64: Du J, Ji H, Ma S, Jin J, Mi S, Hou K, Dong J, Wang F, Zhang C, Li Y, Hu S. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma. *Brief Bioinform*. 2021 Sep 2;22(5):bbab013. doi: 10.1093/bib/bbab013. PMID: 33594424.
- 65: Omar NB, Bentley RT, Crossman DK, Foote JB, Koehler JW, Markert JM, Platt SR, Rissi DR, Shores A, Sorjonen D, Yanke AB, Gillespie GY, Chambers MR. Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas. *Neurosurg Focus*. 2021 Feb;50(2):E5. doi: 10.3171/2020.11.FOCUS20844. PMID: 33524948; PMCID: PMC8383155.
- 66: Tan YQ, Li YT, Yan TF, Xu Y, Liu BH, Yang JA, Yang X, Chen QX, Zhang HB. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma. *Front Immunol*. 2020 Dec 21;11:606164. doi: 10.3389/fimmu.2020.606164. PMID: 33408717; PMCID: PMC7779629.
- 67: Zhang H, Fan F, Yu Y, Wang Z, Liu F, Dai Z, Zhang L, Liu Z, Cheng Q. Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas. *J Transl Med*. 2020 Aug 6;18(1):305. doi: 10.1186/s12967-020-02460-3. Erratum in: *J Transl Med*. 2020 Sep 28;18(1):368. PMID: 32762688; PMCID: PMC7409670.
- 68: Zhang Q, Zhong H, Fan Y, Liu Q, Song J, Yao S, Cao F. Immune and Clinical Features of CD96 Expression in Glioma by *in silico* Analysis. *Front Bioeng Biotechnol*. 2020 Jun 30;8:592. doi: 10.3389/fbioe.2020.00592. Erratum in: *Front Bioeng Biotechnol*. 2020 Oct 23;8:599544. PMID: 32695752; PMCID: PMC7338376.
- 69: Chen Y, Li Q, Zhang J, Gu R, Li K, Zhao G, Yuan H, Feng T, Ou D, Lin P. [Increased TRIM5 is

associated with a poor prognosis and immune infiltration in glioma patients]. *Sheng Wu Yi Xue Gong Cheng Xue Za Zhi*. 2020 Jun 25;37(3):469-479. Chinese. doi: 10.7507/1001-5515.202004064. PMID: 32597089.

70: Wang Y, Zhao B, Chen W, Liu L, Chen W, Zhou L, Kong Z, Dai C, Wang Y, Ma W. Pretreatment Geriatric Assessments of Elderly Patients with Glioma: Development and Implications. *Aging Dis*. 2020 Mar 9;11(2):448-461. doi: 10.14336/AD.2019.0527. PMID: 32257553; PMCID: PMC7069455.

71: Xiao Y, Zhu Z, Li J, Yao J, Jiang H, Ran R, Li X, Li Z. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses. *Aging (Albany NY)*. 2020 Feb 20;12(4):3407-3430. doi: 10.18632/aging.102819. Epub 2020 Feb 20. PMID: 32081833; PMCID: PMC7066912.

72: Packer RJ, Iavarone A, Jones DTW, Blakeley JO, Bouffet E, Fisher MJ, Hwang E, Hawkins C, Kilburn L, MacDonald T, Pfister SM, Rood B, Rodriguez FJ, Tabori U, Ramaswamy V, Zhu Y, Fangusaro J, Johnston SA, Gutmann DH. Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. *Neuro Oncol*. 2020 Jun 9;22(6):773-784. doi: 10.1093/neuonc/noaa036. PMID: 32055852; PMCID: PMC7283027.

73: Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. *Clin Cancer Res*. 2020 Apr 1;26(7):1586-1594. doi: 10.1158/1078-0432.CCR-18-1140. Epub 2020 Feb 7. PMID: 32034072.

74: Martin AM, Bell WR, Yuan M, Harris L, Poore B, Arnold A, Engle EL, Asnaghi L, Lim M, Raabe EH, Eberhart CG. PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status. *J Neuropathol Exp Neurol*. 2020 Jan 1;79(1):74-85. doi: 10.1093/jnen/nlzl119. PMID: 31819973; PMCID: PMC8660581.

75: Lu J, Li H, Chen Z, Fan L, Feng S, Cai X, Wang H. Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma. *Cancer Cell Int*. 2019 Oct 11;19:265. doi: 10.1186/s12935-019-0972-1. PMID: 31632199; PMCID: PMC6788075.

76: Tang X, Zhao S, Zhang Y, Wang Y, Zhang Z, Yang M, Zhu Y, Zhang G, Guo G, Tong A, Zhou L. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. *Mol Ther Oncolytics*. 2019 Jul 23;14:279-287. doi: 10.1016/j.omto.2019.07.002. PMID: 31485480; PMCID: PMC6713854.

77: Eoli M, Saletti V, Finocchiaro G. Neurological malignancies in neurofibromatosis type 1. *Curr Opin Oncol*. 2019 Nov;31(6):554-561. doi: 10.1097/CCO.0000000000000576. PMID: 31436563.

78: Li X, Meng Y. Survival analysis of immune-related lncRNA in low-grade glioma. *BMC Cancer*. 2019 Aug 16;19(1):813. doi: 10.1186/s12885-019-6032-3. PMID: 31419958; PMCID: PMC6697914.

79: Manocha A, Jain S. WT1 in astrocytomas: Comprehensive evaluation of immunohistochemical expression and its potential utility in different histological grades. *Indian J Cancer*. 2019 Jul-Sep;56(3):197-201. doi: 10.4103/ijc.IJC_51_18. PMID: 31389380.

80: Zimmer N, Kim E, Sprang B, Leukel P, Khafaji F, Ringel F, Sommer C, Tuettenberg J, Tuettenberg A. GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of Glioblastoma Multiforme. *Int J Mol Sci*. 2019 Jul 26;20(15):3676. doi: 10.3390/ijms20153676. PMID: 31357555; PMCID: PMC6695992.

- 81: Yeung YT, Fan S, Lu B, Yin S, Yang S, Nie W, Wang M, Zhou L, Li T, Li X, Bode AM, Dong Z. CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. *Carcinogenesis*. 2020 May 14;41(3):377-389. doi: 10.1093/carcin/bgz113. PMID: 31241130; PMCID: PMC7221505.
- 82: Kesarwani P, Prabhu A, Kant S, Chinnaiyan P. Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. *Cancer Immunol Immunother*. 2019 Jul;68(7):1107-1120. doi: 10.1007/s00262-019-02347-3. Epub 2019 May 22. PMID: 31119318; PMCID: PMC6586493.
- 83: Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. *Oncoimmunology*. 2019 Mar 22;8(5):e1581545. doi: 10.1080/2162402X.2019.1581545. PMID: 31069142; PMCID: PMC6492985.
- 84: Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Santi M, Cruz CR, Packer RJ, Almira-Suarez MI, Hwang EI, Nazarian J. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma. *J Neuropathol Exp Neurol*. 2019 May 1;78(5):380-388. doi: 10.1093/jnen/nlz021. PMID: 30990879; PMCID: PMC6467196.
- 85: Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, Mulkearns-Hubert EE, Sinyuk M, Hale JS, Onzi GR, McGraw M, Huang P, Grabowski MM, Wathen CA, Ahluwalia MS, Radivoyevitch T, Kornblum HI, Kristensen BW, Vogelbaum MA, Lathia JD. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. *JCI Insight*. 2018 Nov 2;3(21):e122264. doi: 10.1172/jci.insight.122264. PMID: 30385717; PMCID: PMC6238746.
- 86: Beltrán JQ, Soto-Abraham JE, Vidaurreta-Serrano J, Macias LGC, Apo EG, Ogando-Rivas E. Astrocytic Tumors in Mexico: An Overview of Characteristics and Prognosis in an Open Reference Center for Low-Income Population. *J Neurosci Rural Pract*. 2018 Oct-Dec;9(4):516-521. doi: 10.4103/jnnp.jnnp_106_18. PMID: 30271043; PMCID: PMC6126285.
- 87: Hung AL, Maxwell R, Theodoros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, Jackson C, Ye X, Tyler B, Selby M, Korman A, Barnhart B, Park SM, Youn JI, Chowdhury T, Park CK, Brem H, Pardoll DM, Lim M. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in Glioblastoma. *Oncoimmunology*. 2018 May 24;7(8):e1466769. doi: 10.1080/2162402X.2018.1466769. PMID: 30221069; PMCID: PMC6136875.
- 88: Friedrich M, Bunse L, Wick W, Platten M. Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. *Curr Opin Oncol*. 2018 Nov;30(6):368-374. doi: 10.1097/CCO.0000000000000478. PMID: 30102604.
- 89: Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. *J Natl Cancer Inst*. 2019 Mar 1;111(3):292-300. doi: 10.1093/jnci/djy107. PMID: 29947810; PMCID: PMC6410946.
- 90: Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M. Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. *J Neuropathol Exp Neurol*. 2018 Aug 1;77(8):696-702. doi: 10.1093/jnen/nly045. PMID: 29878245; PMCID: PMC6044395.

- 91: Gorski HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience. *Pediatr Blood Cancer*. 2018 Sep;65(9):e27234. doi: 10.1002/pbc.27234. Epub 2018 May 11. PMID: 29750399.
- 92: Müller S, Agnihotri S, Shoger KE, Myers MI, Smith N, Chaparala S, Villanueva CR, Chattopadhyay A, Lee AV, Butterfield LH, Diaz A, Okada H, Pollack IF, Kohanbash G. Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. *JCI Insight*. 2018 Apr 5;3(7):e98791. doi: 10.1172/jci.insight.98791. PMID: 29618666; PMCID: PMC5928860.
- 93: Li J, Liu X, Duan Y, Wang H, Su W, Wang Y, Zhuang G, Fan Y. Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen- related cell adhesion molecule 1 in patients with glioma. *Oncol Lett*. 2018 Mar;15(3):3496-3503. doi: 10.3892/ol.2018.7786. Epub 2018 Jan 12. PMID: 29467871; PMCID: PMC5796289.
- 94: Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide- associated hypermutation in gliomas. *Neuro Oncol*. 2018 Sep 3;20(10):1300-1309. doi: 10.1093/neuonc/noy016. PMID: 29452419; PMCID: PMC6120358.
- 95: Plant AS, Koyama S, Sinai C, Solomon IH, Griffin GK, Ligon KL, Bandopadhyay P, Betensky R, Emerson R, Dranoff G, Kieran MW, Ritz J. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. *J Neurooncol*. 2018 Apr;137(2):269-278. doi: 10.1007/s11060-017-2737-9. Epub 2018 Jan 10. PMID: 29322427.
- 96: Müller S, Kohanbash G, Liu SJ, Alvarado B, Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E, Malatesta M, Amankulor NM, Kriegstein AR, Lim DA, Aghi M, Okada H, Diaz A. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. *Genome Biol*. 2017 Dec 20;18(1):234. doi: 10.1186/s13059-017-1362-4. PMID: 29262845; PMCID: PMC5738907.
- 97: MacLellan JD, Arnold SA, Dave AC, Hunt MA, Pluhar GE. Association of magnetic resonance imaging-based preoperative tumor volume with postsurgical survival time in dogs with primary intracranial glioma. *J Am Vet Med Assoc*. 2018 Jan 1;252(1):98-102. doi: 10.2460/javma.252.1.98. PMID: 29244602.
- 98: Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S, Lesser GJ, Stogner-Underwood K, Mott RT, Rush SZ, Stanke JJ, Dahiya S, Sun J, Reddy P, Chalmers ZR, Erlich R, Chudnovsky Y, Fabrizio D, Schrock AB, Ali S, Miller V, Stephens PJ, Ross J, Crawford JR, Ramkissoon SH. Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. *Oncologist*. 2017 Dec;22(12):1478-1490. doi: 10.1634/theoncologist.2017-0242. Epub 2017 Sep 14. PMID: 28912153; PMCID: PMC5728033.
- 99: Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J. CD70, a novel target of CAR T-cell therapy for gliomas. *Neuro Oncol*. 2018 Jan 10;20(1):55-65. doi: 10.1093/neuonc/nox116. PMID: 28651374; PMCID: PMC5761579.
- 100: Shao S, Risch E, Burner D, Lu L, Mineev B, Ma W. IFN γ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells. *Int Immunopharmacol*. 2017 Jun;47:159-165. doi: 10.1016/j.intimp.2017.04.003. Epub 2017 Apr 12. PMID: 28410529.

101: Xue S, Hu M, Iyer V, Yu J. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. *J Hematol Oncol*. 2017 Apr 7;10(1):81. doi: 10.1186/s13045-017-0455-6. PMID: 28388955; PMCID: PMC5384128.

102: Sandén E, Enríquez Pérez J, Visse E, Kool M, Carén H, Siesjö P, Darabi A. Preoperative systemic levels of VEGFA, IL-7, IL-17A, and TNF- β delineate two distinct groups of children with brain tumors. *Pediatr Blood Cancer*. 2016 Dec;63(12):2112-2122. doi: 10.1002/pbc.26158. Epub 2016 Jul 29. PMID: 27472224.

103: Eisele SC, Wen PY, Lee EQ. Assessment of Brain Tumor Response: RANO and Its Offspring. *Curr Treat Options Oncol*. 2016 Jul;17(7):35. doi: 10.1007/s11864-016-0413-5. PMID: 27262709.

104: Sims JS, Grinshpun B, Feng Y, Ung TH, Neira JA, Samanamud JL, Canoll P, Shen Y, Sims PA, Bruce JN. Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire. *Proc Natl Acad Sci U S A*. 2016 Jun 21;113(25):E3529-37. doi: 10.1073/pnas.1601012113. Epub 2016 Jun 3. PMID: 27261081; PMCID: PMC4922177.

105: Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly- ICLC in a pilot study for pediatric recurrent low-grade gliomas. *Neuro Oncol*. 2016 Aug;18(8):1157-68. doi: 10.1093/neuonc/now026. Epub 2016 Mar 15. PMID: 26984745; PMCID: PMC4933485.

106: Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse low-grade glioma . *J Neurooncol*. 2015 Dec;125(3):631-5. doi: 10.1007/s11060-015-1865-3. Epub 2015 Nov 3. PMID: 26530260.

107: Dodgshun AJ, Hansford JR, Cole T, Choo S, Sullivan MJ. Reply to Comment on: Carboplatin Hypersensitivity Reactions in Pediatric low-grade glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. *Pediatr Blood Cancer*. 2016 Jan;63(1):175. doi: 10.1002/pbc.25747. Epub 2015 Sep 23. PMID: 26398340.

108: Genc DB, Berrak SG, Canpolat C. Comment on: Carboplatin Hypersensitivity Reactions in Pediatric Low-Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. *Pediatr Blood Cancer*. 2016 Jan;63(1):174. doi: 10.1002/pbc.25734. Epub 2015 Aug 27. PMID: 26313156.

109: Dodgshun AJ, Hansford JR, Cole T, Choo S, Sullivan MJ. Carboplatin Hypersensitivity Reactions in Pediatric low-grade glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. *Pediatr Blood Cancer*. 2016 Jan;63(1):17-20. doi: 10.1002/pbc.25686. Epub 2015 Jul 24. PMID: 26207610.

110: Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. *J Natl Cancer Inst*. 2015 May 13;107(8):djv137. doi: 10.1093/jnci/djv137. PMID: 25971300; PMCID: PMC4554195.

111: Pellegatta S, Valletta L, Corbetta C, Patanè M, Zucca I, Riccardi Sirtori F, Bruzzone MG, Fogliatto G, Isacchi A, Pollo B, Finocchiaro G. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. *Acta Neuropathol Commun*. 2015 Jan 21;3:4. doi: 10.1186/s40478-014-0180-0. PMID: 25849072; PMCID: PMC4359524.

112: Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and neurocognitive outcome. *World Neurosurg*. 2014 Jul-Aug;82(1-2):e299-309. doi:

10.1016/j.wneu.2014.02.033. Epub 2014 Feb 19. PMID: 24560709.

113: Okada H, Scheurer ME, Sarkar SN, Bondy ML. Integration of epidemiology, immunobiology, and translational research for brain tumors. *Ann N Y Acad Sci.* 2013 May;1284(1):17-23. doi: 10.1111/nyas.12115. PMID: 23651189; PMCID: PMC3648859.

114: Shankarkumar U, Sridharan B. Glioma Indian scenario: Is there a human leucocyte antigen association? *J Nat Sci Biol Med.* 2011 Jul;2(2):205-8. doi: 10.4103/0976-9668.92323. PMID: 22346237; PMCID: PMC3276015.

115: Ohta M, Taga T, Nomura A, Kato H, Takano T, Maruo Y, Takeuchi Y, Ishida M, Ohta S. Epstein-Barr virus-related lymphoproliferative disorder, cytomegalovirus reactivation, and varicella zoster virus encephalitis during treatment of medulloblastoma. *J Med Virol.* 2011 Sep;83(9):1582-4. doi: 10.1002/jmv.22136. PMID: 21739449.

116: Wainwright DA, Balyasnikova IV, Han Y, Lesniak MS. The expression of BST2 in human and experimental mouse brain tumors. *Exp Mol Pathol.* 2011 Aug;91(1):440-6. doi: 10.1016/j.yexmp.2011.04.012. Epub 2011 May 1. PMID: 21565182; PMCID: PMC3139740.

117: Genc DB, Canpolat C, Berrak SG. Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. *Support Care Cancer.* 2012 Feb;20(2):385-93. doi: 10.1007/s00520-011-1123-y. Epub 2011 Mar 17. PMID: 21416159.

118: Pluhar GE, Grogan PT, Seiler C, Goulart M, Santacruz KS, Carlson C, Chen W, Olin MR, Lowenstein PR, Castro MG, Haines SJ, Ohlfest JR. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. *Vaccine.* 2010 Apr 26;28(19):3371-8. doi: 10.1016/j.vaccine.2010.02.082. Epub 2010 Mar 1. PMID: 20197146; PMCID: PMC2854671.

119: Rushing EJ, Sandberg GD, Horkayne-Szakaly I. High-grade astrocytomas show increased Nestin and Wilms's tumor gene (WT1) protein expression. *Int J Surg Pathol.* 2010 Aug;18(4):255-9. doi: 10.1177/1066896909338596. Epub 2009 Jul 3. PMID: 19578047.

120: Bodey B, Bodey V, Siegel SE. Expression in childhood primary brain tumors of NY-ESO-1, a cancer/testis antigen: an immunohistochemical study. *In Vivo.* 2008 Jan-Feb;22(1):83-7. PMID: 18396787.

121: Zhang JG, Kruse CA, Driggers L, Hoa N, Wisoff J, Allen JC, Zagzag D, Newcomb EW, Jadus MR. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. *J Neurooncol.* 2008 May;88(1):65-76. doi: 10.1007/s11060-008-9534-4. Epub 2008 Feb 8. PMID: 18259692; PMCID: PMC4005736.

122: Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. *Clin Cancer Res.* 2005 Jul 15;11(14):5292-9. doi: 10.1158/1078-0432.CCR-05-0545. PMID: 16033848.

123: De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciote R, Van Gool SW. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. *J Neurosurg.* 2004 May;100(5 Suppl Pediatrics):492-7. doi: 10.3171/ped.2004.100.5.0492. PMID: 15287461.

124: Hayashi S, Yamamoto M, Ueno Y, Ikeda K, Ohshima K, Soma G, Fukushima T. Expression of

nuclear factor-kappa B, tumor necrosis factor receptor type 1, and c-Myc in human astrocytomas. *Neurol Med Chir (Tokyo)*. 2001 Apr;41(4):187-95. doi: 10.2176/nmc.41.187. PMID: 11381677.

125: Kaiser HE, Bodey B. The role of apoptosis in normal ontogenesis and solid human neoplasms. *In Vivo*. 2000 Nov-Dec;14(6):789-803. PMID: 11204498.

126: Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. *J Neurooncol*. 1999;45(2):141-57. doi: 10.1023/a:1006293606710. PMID: 10778730.

127: Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? *In Vivo*. 1999 Jul-Aug;13(4):357-73. PMID: 10586378.

128: Hildebrand J, Dewitte O, Dietrich PY, de Tribolet N. Management of malignant brain tumors. *Eur Neurol*. 1997;38(3):238-53. doi: 10.1159/000113379. PMID: 9363837.

129: Chatel M, Lebrun C, Frenay M. Chemotherapy and immunotherapy in adult malignant gliomas. *Curr Opin Oncol*. 1993 May;5(3):464-73. doi: 10.1097/00001622-199305000-00005. PMID: 8494907.

130: Nagai M. [Advances of BRM therapy of malignant brain tumors]. *Gan To Kagaku Ryoho*. 1991 Feb;18(2):188-94. Japanese. PMID: 1992912.

131: Jennings MT, Jennings VD, Asadourian LL, Rosenblum M, Albino AP, Cairncross JG, Old LJ. Five novel cell surface antigens of CNS neoplasms. *J Neurol Sci*. 1989 Jan;89(1):63-78. doi: 10.1016/0022-510x(89)90007-5. PMID: 2926443.

132: Sutton LN. Current management of low-grade astrocytomas of childhood. *Pediatr Neurosci*. 1987;13(2):98-107. doi: 10.1159/000120311. PMID: 3325954.

133: Koivukangas J, Koivukangas P. Treatment of low-grade cerebral astrocytoma: new methods and evaluation of results. *Ann Clin Res*. 1986;18 Suppl 47:115-24. PMID: 3545036.

134: Salzman M. The morbidity and mortality of brain tumors. A perspective on recent advances in therapy. *Neurol Clin*. 1985 May;3(2):229-57. PMID: 2991725.

135: Kyuma Y, Yamashita T, Ishiwata Y, Murai M, Kuwabara T. [Treatment of recurrent gliomas]. *No Shinkei Geka*. 1984 Mar;12(4):477-83. Japanese. PMID: 6547513.

From:
<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:
https://neurosurgerywiki.com/wiki/doku.php?id=low-grade_glioma_immunotherapy

Last update: **2024/06/07 02:52**

